Vertex Pharmaceuticals, Inc (VRTX)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Reshma Kewalramani |
| Employees: | 4,800 |
| Web site: | vrtx.com |
|
50 NORTHERN AVENUE, BOSTON, MA, 02210
6173416393
| |
| Date | Ratio |
|---|---|
| 2000-08-24 | 2:1 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.
Please log in first to see chart